KILIÇKAP, S. Et Al. 2019. Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.6 , 1195-1196.

KILIÇKAP, S., Onder, S., DİZDAR, Ö., ERMAN, M., & ÜNER, A., (2019). Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.6, 1195-1196.

KILIÇKAP, SAADETTİN Et Al. "Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability," CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.6, 1195-1196, 2019

KILIÇKAP, SAADETTİN Et Al. "Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.6, pp.1195-1196, 2019

KILIÇKAP, S. Et Al. (2019) . "Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.6, pp.1195-1196.

@article{article, author={SAADETTİN KILIÇKAP Et Al. }, title={Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability}, journal={CANCER CHEMOTHERAPY AND PHARMACOLOGY}, year=2019, pages={1195-1196} }